- Thinly traded nano cap Neuralstem (CUR) perks up 2% premarket, albeit on only 800 shares, in response to its announcement of encouraging preclinical results for stem cell therapy candidate NSI-566. The data were published recently in the Journal of Neurotrauma.
- In a rat model of penetrating ballistic-like brain injury (PBBI), NSI-566 transplanted 7 - 10 days after PBBI showed vigorous engraftment and long-term survival. There was evidence of neuronal differentiation after four months and axons (threadlike parts of nerve cells that conduct electrical impulses) from grafted cells extended a significant distance from the graft site.
- Preclinical testing in ongoing.